A day after IBM’s preliminary second-quarter figures wiped roughly €68 billion from its market capitalization in the worst single-day rout the company has seen in decades, at least half a dozen law firms have begun investigating whether the technology giant misrepresented the strength of its sales pipeline. The probe centers on disclosure practices around the z17 mainframe cycle, a product line that management had earlier described as having the “strongest launch” in the company’s history. The question now being asked by both legal teams and shareholders is whether the upbeat narrative masked structural headwinds that became apparent only when the preliminary numbers landed on July 14.
The reaction was brutal. IBM stock plunged more than 25% in a single session, erasing tens of billions in equity value. The shares closed that day near a 52-week low of €178.52 and have since recovered only modestly to €184.64 – still roughly 37% below the year’s high of €292.85, reached on June 1. The 30-day implied volatility has surged above 83%, and the relative strength index of 31.2 puts the stock deep in oversold territory. Investors are pricing in a high degree of uncertainty, and the legal scrutiny adds another layer of risk.
The trigger was a set of preliminary quarterly figures that missed Wall Street’s consensus by a wide margin. Revenue came in at $17.2 billion, up just 1% from a year earlier but well short of the $17.86 billion analysts had expected. Operating earnings per share landed at $2.93, versus an estimate of $3.02. The shortfall was broad, but CEO Arvind Krishna supplied an unusual explanation in a letter to shareholders: clients had reallocated capital late in the quarter, shifting spending away from software and infrastructure services toward servers, storage, and memory chips – essentially racing to secure tight hardware supplies before prices rose.
That narrative is borne out in the segment details. Infrastructure revenue fell 7% overall, but within that category the picture was more nuanced. Distributed infrastructure surged 37% as customers loaded up on AI-capable servers, while the higher-margin mainframe business struggled. Software rose 5%, supported by an 11% acceleration at Red Hat on a quarterly basis, but consulting was essentially flat on a constant-currency basis and failed to provide the ballast IBM typically counts on. Krishna also cited cybersecurity-related distractions that delayed a number of large deals, pushing their closure beyond the quarter.
Should investors sell immediately? Or is it worth buying IBM?
This is where the legal investigations gain traction. The management had touted the z17’s early performance as the strongest mainframe launch in the company’s history when it debuted earlier this year. The weak preliminary Q2 results now put that claim under a microscope. Law firms are examining whether IBM provided an overly optimistic view of its deal pipeline and the z17 replacement cycle, thereby misleading investors before the stock collapsed. If the allegations are substantiated, the case could turn on what executives knew about the pacing of enterprise spending and how that information was communicated to the market.
Wall Street analysts have responded with caution. Jefferies lowered its price target from $320 to $260 on July 21 but maintained a buy rating, a sign that the deterioration is seen as cyclical rather than structural. The consensus analyst target stands at around €270, implying roughly 46% upside from current levels – a gap that can only close if IBM delivers a convincing turnaround story. On July 22, the company is scheduled to release full quarterly results and hold a conference call. The market expects management to provide clarity on the delayed deals, an updated full-year outlook, and concrete progress on AI initiatives such as those built on Red Hat and watsonx.
One bright spot has been free cash flow, which reached €4.8 billion in the first half and underpins a dividend yield of 3.2%. That gives long-term holders some comfort, but it is not enough to change the calculus for the broader investor base. Krishna, who in his own letter described the quarter as having “stumbled,” now faces the dual challenge of rebuilding credibility while defending the company’s franchise against an intensifying legal headwind. Wednesday’s earnings call could determine whether the stock begins a recovery or slips further into the quagmire of litigation and doubt.
Ad
IBM Stock: Buy or Sell?! New IBM Analysis from July 21 delivers the answer:
The latest IBM figures speak for themselves: Urgent action needed for IBM investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 21.
IBM: Buy or sell? Read more here...
